AddedRisk Factors
Risks and uncertainties that we face with respect to our patents and patent applications include the following:
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
The Company’s business is subject to risks related to, among other factors, tariffs and other trade protection measures put in place by the United States and other countries. The U.S. government has implemented or is in the process of implementing various tariffs on the importation of goods from certain countries, a number of which are applicable to the Company’s supply chain, operations, and sales, and the tariffs enacted or proposed by the Trump Administration and retaliatory tariffs by other countries could make it significantly more difficult or costly for the Company to import certain products or materials to the United States, or export products or materials from the United States to other countries. Currently, a small portion of the products, materials, and components used in our products are imported from China, and a significant share of the dental equipment that we sell in the United States is manufactured in Europe. Europe is also a major market for our products, including certain consumable products made in the United States, while sales in China represent less than 5% of our global sales on an annual basis. We continue to monitor and evaluate the ongoing and potential impacts of the tariffs and changes in trade policy, whether implemented or proposed, on our supply chain, costs, net sales and profitability. We have implemented and continue to evaluate additional strategies that would mitigate such impacts, including competitive pricing strategies to offset tariffs and evaluating potential sourcing options that work with our vendors and merchants to seek to minimize products sourced from high tariff rate countries, both for existing products and for new product development. Furthermore, changes in trade policies can lead to supply chain constraints, higher energy costs, labor shortages, and contribute to the risk of higher inflation and general economic uncertainty across the industry and the regions in which the Company operates. The impact that these tariffs and changes in trade policy will ultimately have on our financial results remains uncertain, including the impact on demand for our products in certain markets if prices rise as a consequence of import tariffs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Furthermore, geopolitical conflicts are expected to continue to shape market dynamics and pose general threats to financial stability in affected regions, including ongoing tensions from both the Russia-Ukraine conflict and the conflict in the Middle East. These conflicts are highly unpredictable and could lead to significant market and other disruptions, which along with the spillover effect of ongoing civil, political, and economic disturbances on surrounding areas, may significantly devalue currencies we use or have other adverse impacts, including increased costs of raw materials, manufacturing or shipping delays or increases in inflation rate, cyberattacks and supply chain challenges.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
continue to do so. For further information, see Note 21, Commitments and Contingencies, discussing the securities class action lawsuits, in the Notes to Consolidated Financial Statements in Item 8 of this Form 10-K.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
The following is a summary of the significant risk factors that could materially impact our business, financial condition or future results, including risks related to our businesses, our international operations, our regulatory environments, ownership of our common stock, and other general risks:
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Our failure to protect our proprietary technology could have an adverse impact on our competitive position.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Our financial results may be adversely impacted if our products or services are found to infringe upon the intellectual property rights of others.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Management previously identified material weaknesses in our internal control over financial reporting, some of which resulted in errors in previously issued financial statements. These material weaknesses were all remediated as of December 31, 2023. If we experience additional material weaknesses in the future, we may be unable to accurately and timely report financial results or comply with the requirements for public companies, which could cause the price of our common stock to decline or limit our access to the capital markets.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Lack of global standardized processes could result in control deficiencies and adversely impact management’s assertions and financial reporting.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•If we fail to comply with laws and regulations relating to health care fraud, we could suffer penalties or be required to make significant changes to our operations, which could adversely affect our business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Climate change and related natural disasters could negatively impact our business and financial results.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Expectations relating to environmental, social and governance considerations may expose us to potential liabilities, increased costs, reputational harm, and other adverse effects on our business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Additionally, we seek to maintain insurance coverage for cybersecurity risks, but such insurance has become increasingly difficult to secure and, in some cases, policies may not provide adequate coverage for possible losses. Further, as cybersecurity risks evolve, such insurance may not be available to us on commercially reasonable terms, or at all. Uninsured losses or operational losses that result from large deductible payments under commercial insurance coverage might have an adverse impact on our business operations, financial position or results of operations.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
to protect the privacy and security of protected health information (“PHI”) and to provide notification in the event of a breach of PHI. The U.S. Department of Health and Human Services Office for Civil Rights (“OCR”), which is responsible for enforcing HIPAA, also may enter into resolution agreements requiring the payment of civil money penalties and/or the establishment of corrective action plans to address violations of HIPAA. Pursuant to HIPAA, OCR has adopted privacy regulations to govern the use and disclosure of PHI and data security regulations that require the implementation of safeguards to protect electronic PHI.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Moreover, global regulation related to the provision of services on the Internet is increasing, as governments continue to adopt new laws and regulations addressing data privacy and the collection, processing, storage and use of personal information. Such laws and regulations are subject to new and differing interpretations and may be inconsistent among jurisdictions. These and other requirements could restrict our ability to store and process data or impact our ability to offer future digital dentistry products and services in certain locations. The costs of compliance with and other burdens imposed by these types of laws, regulations and standards may limit the adoption of our products or services or lead to significant fines, penalties or liabilities for noncompliance, any of which could harm our business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We generate a substantial portion of our revenue through a limited number of distributors that provide important support to end-users. Together, our two largest distributors, Patterson Companies, Inc. (“Patterson”) and Henry Schein, Inc. (“Henry Schein”), accounted for approximately 13% of our annual revenue for the year ended December 31, 2024. In July 2024, we delivered a one-year notice of non-renewal to Patterson in connection with its non-exclusive distribution agreements for the distribution of dental equipment in the United States and Canada. It is anticipated that Patterson will continue to be one of our two largest distributors as a percentage of our global revenue during the one-year notice period. We intend to engage in discussions for new distribution agreements with Patterson. However, failure to successfully renegotiate the distribution agreements or secure new agreements with another distributor could have a material adverse effect on our business, operating results and financial condition. We have not incurred any charges against earnings in 2024 related to non-renewal of the distribution agreements.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
An adverse determination in such proceedings could subject us to significant liabilities, allow our competitors to market competitive products without obtaining a license from us, prohibit us from marketing our products or products, require us to seek licenses from third parties. parties, require us to pay substantial damages, including but not limited to treble damages, attorneys’ fees and costs, for past infringement, or we could be at risk for an injunction if it is ultimately determined that our products infringe a third party’s intellectual property rights.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If Patterson or Henry Schein ceases to purchase a significant volume of products from us, or if changes Changes in our distributors, our promotional strategies strategies, and investments result in changes in may adversely impact our distributor relationships, it including their effectiveness in selling our projects, which could have a material adverse effect on our results of operations and financial condition.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In January 2025, we announced that Byte aligners would no longer be offered to new patients, and we now plan to utilize certain Byte resources elsewhere in the aligners portfolio to create orthodontic demand, support a digital clinical workflow, enhance the customer experience, and improve patient monitoring. patients.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have Actual performance of acquired other companies and intangible assets and may not realize all differ from forecasts or projections, leading to the anticipated economic benefit from those acquisitions, acquisitions not being realized, which could cause result in an impairment of goodwill or intangibles. intangible assets.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
These regulations applied to all medical device manufacturers who market their medical devices in the EU, and manufacturers were required to perform significant upgrades to quality systems and processes On March 20, 2023, the EU Commission extended the MDR transitional periods until December 31, 2027 for higher risk devices and until December 31, 2028 for other medical devices. processes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
These regulations applied to all medical device manufacturers who market their medical devices in the EU, and manufacturers were required to perform significant upgrades to quality systems and processes On March 20, 2023, the EU Commission extended the MDR transitional periods until December 31, 2027 for higher risk devices and until December 31, 2028 for other medical devices.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, a significant portion of our injectable anesthetic products, orthodontic products, certain dental cutting instruments, catheters, nickel titanium products and certain other products and raw materials are purchased from a limited number of suppliers and suppliers, including in certain cases single source suppliers pursuant to agreements that are subject to periodic renewal, some of which may also compete with us.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The EU General Data Protection Regulation (“GDPR”), for example, imposes has an extraterritorial scope that makes it applicable to our U.S.-based legal entities whenever we process the personal data of EU residents and impose stringent data protection requirements and provides significant penalties for noncompliance.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Due Additional changes to the large scale tax laws or inconsistent application of our global business activities, the enactment of existing tax laws, including Pillar Two legislation Two, could increase tax uncertainty and have a material effect on the Company’s effective tax rate, financial position, results of operations, and cash flows.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In the United States, the federal Health Insurance Portability and Accountability Act of 1996, as amended, and its implementing regulations (collectively, “HIPAA”) impose certain requirements on covered entities and their business associates to protect the privacy and security of protected health information (“PHI”) and to provide notification in the event of a breach of PHI.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We may also incur charges related to undertake restructuring plans that are lead to our incurring charges to execute the plans, which charges may be higher than anticipated, which would reduce reducing our profitability in the periods such charges are incurred.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
There can be no assurance that our distribution partners will purchase any minimum quantity of products from us or that they will continue to purchase any products at all. a similar rate as in the past.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We remain focused on ensuring that all our applicable medical device products will be fully certified by the deadlines.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The Company conducts business through four reportable segments: (1) Connected Technology Solutions, (2) Essential Dental Solutions, (3) Orthodontic and Implant Solutions, and (4) Wellspect Healthcare.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
As previously disclosed in the Company’s Current Report on Form 8-K filed January 14, 2026, the Company entered into new non-exclusive distribution agreements with Patterson Dental Holdings, a leading supplier of products and services to the dental health end market, for the distribution of dental equipment in the United States. This renewed partnership reflects both companies’ commitment to supporting dental professionals with advanced technologies and expert service while setting a clear focus on driving growth and innovation in the years ahead.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Various headwinds are expected to weigh on global growth in 2026, due in large part to increasing uncertainties related to global trade policies and inflation. Changes in trade policy, supply chain constraints, higher energy costs, labor shortages, and geopolitical tensions have all contributed to the risk of higher inflation and general economic uncertainty across the industry and the regions in which the Company operates.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The challenging macroeconomic conditions have impacted consumer confidence, the ability and willingness of clinicians to obtain financing to purchase equipment, and consumer discretionary spending for elective procedures, leading to adverse impacts on the Company’s results of operations, particularly in the United States. The Company has taken actions to attempt to mitigate the effects of challenging macroeconomic conditions and may take further actions in the future.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
As disclosed in Part I, Item 1A, “Risk Factors,” the Company’s business is subject to risks related to, among other factors, tariffs and other trade protection measures put in place by the United States and other countries. The U.S. government has implemented or is in the process of implementing various tariffs on the importation of goods from certain countries, a number of which are applicable to the Company’s supply chain, operations, and sales, and the tariffs enacted or proposed by the Trump Administration and retaliatory tariffs by other countries could make it significantly more difficult or costly for the Company to import certain products or materials to the United States, or export products or materials from the United States to other countries. Currently, a small portion of the products, materials, and components used in our products are imported from China, and a significant share of the dental equipment that we sell in the United States is manufactured in Europe. Europe is also a major market for our products, including certain consumable products made in the United States, while sales in China represent less than 5% of the Company’s global sales on an annual basis. We continue to monitor and evaluate the ongoing and potential impacts of the tariffs and changes in trade policy, whether implemented or proposed, on our supply chain, costs, net sales and profitability. We have implemented and continue to evaluate additional strategies that would mitigate such impacts, including competitive pricing strategies to offset tariffs and evaluating potential sourcing options that work with our vendors and merchants to seek to minimize products sourced from high tariff rate countries, both for existing products and for new product development. The impact that these tariffs and changes in trade policy will ultimately have on our financial results remains uncertain, including the impact on demand for our products in certain markets if prices rise as a consequence of import tariffs. For additional information, see Part I, Item 1A, “Risk Factors”.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Geopolitical conflicts are expected to continue to shape market dynamics and pose general threats to financial stability in affected regions, including ongoing tensions from both the Russia-Ukraine conflict and the conflict in the Middle East. Overall, the Company’s operations in Russia, Ukraine, and Israel have not been materially impacted by these conflicts.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Net sales by segment and percentage changes in net sales as reported and on a constant currency basis were as follows:
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Percentage Change Net Sales by Segment (in millions, except percentages) 2025 vs. 2024 United States Europe Rest of World 2025 2024 As Reported1 Constant Currency1 As Reported Constant Currency As Reported Constant Currency As Reported Constant Currency Connected Technology Solutions $ 1,036 $ 1,062 (2.5)% (3.8)% (12.4)% (12.4)% 5.8% 1.6% (2.8)% (2.0)% Essential Dental Solutions 1,469 1,454 1.1% (0.2)% (4.3)% (4.4)% 3.9% (0.1)% 5.4% 6.3% Orthodontic and Implant Solutions 850 973 (12.6)% (13.4)% (24.6)% (24.6)% (0.5)% (3.7)% (8.4)% (6.9)% Wellspect Healthcare 325 304 6.6% 3.9% 2.6% 4.0% 6.3% 2.7% 35.4% 36.2% Total $ 3,680 $ 3,793 (3.0)% (4.3)% (12.3)% (12.3)% 3.8% —% (0.6)% 0.4% (1) Constant currency sales are a Non-GAAP measure in which the reported net sales are adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period’s currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The total net sales decrease on a constant currency basis was driven by lower volumes in the Orthodontic and Implant Solutions segment as a result of the suspension of Byte sales, as well as lower volumes of CAD/CAM and implants products, particularly in the United States. The decrease was partially offset by higher volumes of preventive and restorative and treatment centers products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The net sales decrease on a constant currency basis was primarily driven by higher customer incentives on preventive and restorative products. The decrease was partially offset by higher volumes of preventive and restorative products and new endodontics products. Volumes for consumables products held by distributors at December 31, 2025 decreased by approximately $4 million compared to the beginning of 2025, and volumes for consumables products at December 31, 2024
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The net sales decrease on a constant currency basis was driven by lower volumes of clear aligners in the United States, primarily related to the suspension of Byte sales, as well as lower volumes for implants and prosthetics products. The decrease was partially offset by higher volumes of orthodontic products in Europe. Additionally, during 2025, the Company refined its estimate of expected customer refunds for the Byte aligner business, resulting in a $14 million adjustment that increased sales, which also partially offset the decrease to net sales.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Gross profit as a percentage of net sales decreased primarily due to unfavorable product mix and pricing for CAD/CAM, implants, imaging, and tariff costs. These decreases were partially offset by a benefit from foreign currency translation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand the Company’s operations and business environment. MD&A is provided as a supplement to, and should be read in conjunction with, the Consolidated Financial Statements and Notes to Consolidated Financial Statements contained in Item 8 of this Form 10-K. The following discussion includes forward-looking statements that involve certain risks and uncertainties. See Part I, Item 1, “Business - Forward-Looking Statements and Associated Risks.”
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
A description of the products and services provided within each of the Company’s four reportable segments is provided below.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
This segment includes the design, manufacture, and sales of the Company’s dental technology and equipment products. These products include the Equipment & Instruments and CAD/CAM product categories. Dental CAD/CAM technologies are products designed for dental professionals to support numerous digital workflows for procedures such as dental restorations through integrations with DS Core, our cloud-based platform.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
This segment includes the development, manufacture, and sales of the Company’s value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Offerings in this segment also include specialized treatment products including products used in the creation of dental appliances.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
This segment includes the design, manufacture, and sales of the Company’s various digital implant systems and innovative dental implant products, digital dentures and dental professional-directed aligner solutions. Offerings in this segment also include application of our digital services and technology, including those provided by DS Core, our cloud-based platform.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
This segment includes the design, manufacture, and sales of the Company’s innovative continence care solutions for both urinary and bowel management. This category consists mainly of urology catheters and other healthcare-related consumable products.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
As previously disclosed in the Company’s Current Report on Form 8-K filed February 11, 2025, the Company has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business. There is no deadline or definitive timetable set for completion of the strategic alternatives process or assurance that the process will result in a transaction. The Company does not intend to make further announcements regarding the review of strategic alternatives unless and until the Board of Directors approves a course of action or otherwise determines further disclosure is appropriate or necessary.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Markets in several regions, particularly Europe, continue to experience varying degrees of pressures inhibiting growth and face concerns about the systemic impacts of adverse economic conditions and geopolitical events. Changes in economic conditions, supply chain constraints, higher energy costs, labor shortages, the conflict in Ukraine, and geopolitical tensions in the Middle East and Russia, have all contributed to a period of higher inflation across the industry and the regions in which the Company operates. As a result, the Company has experienced higher prices for certain raw materials, including electronic components, which have led to a negative impact on margins. We expect a continuation of inflationary pressure on the cost of both raw materials and wages into 2025, the effect of which will depend on our ability to successfully mitigate and offset the related impacts.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
The challenging macroeconomic conditions have also negatively impacted demand for the Company’s products and may continue to do so in the future. Specifically, higher interest rates have put pressure on the ability and willingness of our customers to obtain financing for equipment purchases, which adversely affects volumes for these products. The higher cost of borrowing has also reduced patient demand for elective dental procedures, which affects sales of the Company’s offerings more broadly. The Company has also faced additional competitive pressure for lower-priced options for equipment and other products by dental practices, in particular for imaging products and implants. While the Company has taken steps to address competitive pressures, such as the reintroduction of its Orthophos SL 2D and 3D products, these trends may continue. While patient volumes have largely remained stable in the United States, the impact of macroeconomic declines and high interest rates has been particularly apparent in Germany, which represented 11% of the Company’s sales for the year ended December 31, 2024. Germany was in a recession for most of 2023, largely due to persistent high inflation and falling household spending. Although conditions, including inflation, marginally improved in 2024, demand for investments in new dental equipment continued to be weak, and economic forecasts by the German government project limited growth in 2025. The Company anticipates that the challenging macroeconomic and market conditions in Germany are likely to persist and negatively impact sales of equipment into next year.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
In anticipation of a continued inflationary trend and potentially deteriorating macroeconomic environment, we have attempted to mitigate these pressures through the following actions, among others:
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•Driving strategic procurement initiatives to leverage alternative sources of raw materials and transportation;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•Implementing cost-containment measures, as well as intensifying continuous improvement and restructuring programs in our manufacturing and distribution facilities and other areas of our business, including the most recent restructuring plan approved by the Board of Directors on July 29, 2024;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
(in millions) Within Years 2-3 Years 4-5 Greater Total 1 Year Than 5 Years (in millions) Long-term borrowings, including finance leases $ 128 228 $ 300 287 $ 227 914 $ 1,093 847 $ 1,748 2,276 Operating leases 52 61 28 10 151 64 26 12 154 Purchase commitments 194 112 40 141 105 — 346 — 246 Interest on long-term borrowings, net of interest rate swap agreements 41 73 64 17 195 46 84 72 1,099 1,301 Postemployment obligations 25 51 46 131 253 31 61 60 145 297 Precious metal consignment agreements 34 49 — — — 34 49 $ 474 547 $ 597 601 $ 405 1,072 $ 1,251 2,103 $ 2,727 4,323
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, the number of days for sales outstanding in accounts receivable decreased increased by 4 7 days to 62 days at December 31, 2025 as compared to 55 days at December 31, 2024 as compared to 59 days at December 31, 2023, 2024, and the number of days of sales in inventory decreased increased by 2 7 days to 131 days at December 31, 2025 as compared to 124 days at December 31, 2024 as compared to 126 days at December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, (in millions, except percentages) 2025 2024 2023 $ Change % Change Selling, general, and administrative expenses $ 1,438 $ 1,605 $ 1,613 $ (8) (0.4 (167) (10.4 Research and development expenses 150 165 184 (19) (10.5 (15) (9.0 Goodwill and intangible asset impairments 650 1,014 307 707 NM (364) (35.9 Restructuring costs 24 53 67 (14) NM (29) (54.7 SG&A as a percentage of net sales 39.1 % 42.3 % 40.7 % 160 (320) bps R&D as a percentage of net sales 4.1 % 4.3 % 4.6 % (30) (20) bps
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The cash Cash used in by investing activities increased decreased compared to the prior year primarily due to higher lower capital expenditures of $31 million, $49 million and lower net cash proceeds payments on settlement of derivatives of $38 million, and in the prior year, the Company’s sale of a minority interest investment resulted in proceeds of $13 $7 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Other (income) expense, net for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023 2024 was as follows:Year Ended December 31, (in millions) 2025 2024 2023 $ Change Foreign exchange gains (a) (32) (21) (3) (18) Loss from equity method investments — 4 (4) (11) Defined benefit pension plan expenses 8 7 1 8 — Other non-operating loss — 1 1 — (1) Other (income) expense, income, net $ (24) $ (12) $ 9 $ (21) (12)
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Also, the Company distributes approximately two-thirds of its dental consumable and technology and equipment products through third-party distributors whose inventory levels tend to may increase in the period leading up to a price increase and decline in the period following the implementation of a price increase, although these the Company seeks to anticipate and limit material fluctuations are mitigated by limits on purchases ahead of these increases. in purchasing behavior as applicable.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Other Income and ExpensesYear Ended December 31, (in millions, except percentages) 2025 2024 2023 $ Change % Change Interest expense, net $ 69 $81 $ 88 $69 $19 28.2% Other income, net (24) (12) (14.5 Other (income) expense, net (12) 9 (21) NM 93.8% Net interest and other expense income $ 57 $90 $ (33) 64 $57 $7
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For further information, see information on each of these segments including the product lines which comprise them, refer to Item 8, Note 11, Goodwill 6, Segment and Intangible Assets, Geographic Information, in the Notes to Consolidated Financial Statements in Item 8 of this Form 10-K.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The Company expects to continue to maintain has historically maintained a level of investment in R&D that is at least 4% of annual net sales. sales, and the Company plans to increase this to at least 5% of annual net sales beginning in 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, (in millions, except percentages) (a) 2025 2024 2023 $ Change % Change Connected Technology Solutions $ 52 $ 70 $ 101 $ (31) (30.3 (18) (25.7 Essential Dental Solutions 514 479 478 1 0.2 35 7.3 Orthodontic and Implant Solutions 108 80 156 (76) (48.6 28 35.0 Wellspect Healthcare 102 98 87 11 12.7 4 4.1
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Operating activities $ 235 $ 461 $ 377 $ 84 (226) Investing activities (132) (197) (89) (108) 65 Financing activities (80) (302) (307) 5 222 Effect of exchange rate changes on cash and cash equivalents 31 (24) (12) (12) 55 Net decrease increase (decrease) in cash and cash equivalents $ 54 $ (62) $ (31) $ (31) 116
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by operating activities increased decreased compared to the prior year primarily as a result of lower sales and changes in working capital, including higher collections on accounts receivable due largely to timing of sales and customer remittances, decreased remittances and higher build of inventory levels, and timing of estimated tax payments. during the current period.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
The Company recognizes in the consolidated financial statements the impact of a tax position if the Company believes that position is more likely than not of being sustained upon examination by the taxing authorities based on the technical merits of the position.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
If the financial institutions would discontinue offering these consignment arrangements, and if the Company could not obtain other comparable arrangements, the Company may be required to obtain third-party financing to fund an ownership position to maintain precious metal inventory at operational levels.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new